Evaluating biomarkers in metastatic castration-resistant prostate cancer patients treated with enzalutamide: PSA, circulating tumor cell counts, AR-V7 status and radiographic progression.

Shruti U. Gandhy,Fatima Karzai,Jennifer L. Marte,Marijo Bilusic,Sheri McMahon,Julius Strauss,Anna Couvillon,Monique Williams,Amy Hankin,Seth M. Steinberg,Audrey Gill,Alisa Tubbs,Joseph Schonhoft,William D. Figg,Philip M. Arlen,William L. Dahut,James L. Gulley,Ravi A. Madan

Evaluating biomarkers in metastatic castration-resistant prostate cancer patients treated with enzalutamide: PSA, circulating tumor cell counts, AR-V7 status and radiographic progression.

2020

Shruti U. Gandhy
Fatima Karzai
Jennifer L. Marte
Marijo Bilusic
Sheri McMahon
Julius Strauss
Anna Couvillon
Monique Williams
Amy Hankin
Seth M. Steinberg
Audrey Gill
Alisa Tubbs
Joseph Schonhoft
William D. Figg
Philip M. Arlen
William L. Dahut
James L. Gulley
Ravi A. Madan

e17569Background: Enzalutamideis ahighly effective treatment in metastatic castration resistant prostate cancer (mCRPC). Although Prostate Cancer Working Group (PCWG) guidelines recommend continuin...

Keywords:

Enzalutamide
Internal medicine
Oncology
Pathology
Prostate cancer
Radiography
castration resistant
Biomarker (medicine)
Medicine
Circulating tumor cell

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations